Class Action Lawsuit Filed Against Aquestive
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy AQST?
Source: Globenewswire
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Aquestive Therapeutics in New Jersey on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, indicating significant issues with the company's drug approval process.
- FDA Deficiency Disclosure: The complaint alleges that during the class period, Aquestive misled investors by claiming its New Drug Application (NDA) would receive timely FDA approval, while in reality, the FDA identified deficiencies that delayed the approval of Anaphylm.
- Stock Price Plunge: Following the announcement on January 9, 2026, that the FDA had identified deficiencies, Aquestive's stock price plummeted over 37% from $6.21 per share on January 8 to $3.91, reflecting strong market concerns about the company's future.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, indicating that the legal action could have significant implications for the company's financial outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AQST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.090
Low
6.00
Averages
9.00
High
12.00
Current: 4.090
Low
6.00
Averages
9.00
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against Aquestive
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Aquestive Therapeutics in New Jersey on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, raising concerns about the company's compliance and transparency.
- Allegation Details: The complaint alleges that during the class period, Aquestive misled investors by claiming its New Drug Application (NDA) would be approved by January 31, 2026, while the FDA identified deficiencies that delayed the approval of Anaphylm, undermining investor confidence.
- Stock Price Impact: Following the announcement on January 9, 2026, that the FDA had identified deficiencies, Aquestive's stock price plummeted over 37% from $6.21 on January 8 to $3.91, reflecting a pessimistic outlook from the market regarding the company's future.
- Next Steps: Investors must apply by May 4, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to assist affected investors in understanding their legal rights and potential compensation options.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 4, 2026.
- FDA Feedback Delays: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its Anaphylm drug NDA, preventing labeling discussions and indefinitely delaying approval, which negatively impacts the company's future revenue expectations.
- Stock Price Plunge: Following the FDA's negative feedback, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 on January 9, 2026, reflecting the market's pessimism regarding the company's outlook.
- Legal Background: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members, showcasing its influence in the legal field.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as attorney fees will be collected through a contingency fee arrangement, which minimizes financial risk for investors by ensuring they only pay if they win.
- Case Background: The lawsuit alleges that the defendants made false or misleading statements and failed to disclose the true state of Aquestive's New Drug Application (NDA), particularly concealing human factors related to the use of its sublingual film, resulting in investor losses when the truth emerged, highlighting issues of corporate governance and transparency.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, indicating their expertise and success rate in this field, thus investors should carefully select experienced legal counsel.
See More
Gross Law Firm Alerts Aquestive Therapeutics Shareholders
- Shareholder Alert: The Gross Law Firm has issued a notice to shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, encouraging them to contact the firm for potential lead plaintiff appointment, indicating significant losses may be involved in the case.
- FDA Feedback Impact: On January 9, 2026, Aquestive announced it received a letter from the FDA identifying deficiencies in its Anaphylm drug application, which precluded labeling discussions, directly affecting investor confidence and leading to a sharp decline in stock price.
- Stock Price Volatility: Following the FDA notification, Aquestive's stock plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, representing a decline of over 37% in a single day, reflecting extreme market pessimism regarding the company's prospects.
- Litigation Participation Opportunity: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, and upon registration, they will receive real-time updates on the case's progress, demonstrating the firm's commitment to protecting investor rights.
See More
Investigation into Aquestive Therapeutics' Risk Disclosures
- Stock Price Plunge: On January 9, 2026, Aquestive's shares plummeted from $6.21 to $3.91, resulting in a single-day loss of $2.30 per share, over 37%, reflecting investor concerns over FDA regulatory deficiencies.
- Inadequate Risk Disclosures: Between June 16, 2025, and January 8, 2026, Aquestive's SEC filings utilized standard risk factor language without specifying known issues affecting the Anaphylm NDA, leaving investors unaware of the actual risk profile.
- Legal Challenge: A lawsuit has been filed by investors questioning the company's failure to disclose specific regulatory hurdles, arguing that generic risk warnings cannot substitute for specific known issues, thereby undermining investor rights.
- Investor Rights Protection: Levi & Korsinsky LLP is evaluating the eligibility of affected investors for claims, with a deadline of May 4, 2026, highlighting the importance of legal support for investor rights and recovery of losses.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, seeking damages for investors who purchased securities between June 16, 2025, and January 8, 2026, highlighting serious concerns over the company's compliance and transparency.
- Legal Allegations Details: The complaint alleges that the defendants made materially false and misleading statements and failed to disclose critical information during the relevant period, potentially leading to investor losses and exacerbating market concerns regarding the company's financial health.
- Investor Participation Opportunity: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, allowing them to share in any potential recovery from the lawsuit, thus providing a chance for investors to recover losses.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in investor rights and securities fraud class actions, having recovered hundreds of millions for investors, underscoring its significant role in upholding market integrity.
See More
Class Action Lawsuit Filed Against Aquestive
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Aquestive Therapeutics in New Jersey on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, raising concerns about the company's compliance and transparency.
- Allegation Details: The complaint alleges that during the class period, Aquestive misled investors by claiming its New Drug Application (NDA) would be approved by January 31, 2026, while the FDA identified deficiencies that delayed the approval of Anaphylm, undermining investor confidence.
- Stock Price Impact: Following the announcement on January 9, 2026, that the FDA had identified deficiencies, Aquestive's stock price plummeted over 37% from $6.21 on January 8 to $3.91, reflecting a pessimistic outlook from the market regarding the company's future.
- Next Steps: Investors must apply by May 4, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to assist affected investors in understanding their legal rights and potential compensation options.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 4, 2026.
- FDA Feedback Delays: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its Anaphylm drug NDA, preventing labeling discussions and indefinitely delaying approval, which negatively impacts the company's future revenue expectations.
- Stock Price Plunge: Following the FDA's negative feedback, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 on January 9, 2026, reflecting the market's pessimism regarding the company's outlook.
- Legal Background: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members, showcasing its influence in the legal field.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as attorney fees will be collected through a contingency fee arrangement, which minimizes financial risk for investors by ensuring they only pay if they win.
- Case Background: The lawsuit alleges that the defendants made false or misleading statements and failed to disclose the true state of Aquestive's New Drug Application (NDA), particularly concealing human factors related to the use of its sublingual film, resulting in investor losses when the truth emerged, highlighting issues of corporate governance and transparency.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, indicating their expertise and success rate in this field, thus investors should carefully select experienced legal counsel.
See More
Gross Law Firm Alerts Aquestive Therapeutics Shareholders
- Shareholder Alert: The Gross Law Firm has issued a notice to shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, encouraging them to contact the firm for potential lead plaintiff appointment, indicating significant losses may be involved in the case.
- FDA Feedback Impact: On January 9, 2026, Aquestive announced it received a letter from the FDA identifying deficiencies in its Anaphylm drug application, which precluded labeling discussions, directly affecting investor confidence and leading to a sharp decline in stock price.
- Stock Price Volatility: Following the FDA notification, Aquestive's stock plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, representing a decline of over 37% in a single day, reflecting extreme market pessimism regarding the company's prospects.
- Litigation Participation Opportunity: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, and upon registration, they will receive real-time updates on the case's progress, demonstrating the firm's commitment to protecting investor rights.
See More
Investigation into Aquestive Therapeutics' Risk Disclosures
- Stock Price Plunge: On January 9, 2026, Aquestive's shares plummeted from $6.21 to $3.91, resulting in a single-day loss of $2.30 per share, over 37%, reflecting investor concerns over FDA regulatory deficiencies.
- Inadequate Risk Disclosures: Between June 16, 2025, and January 8, 2026, Aquestive's SEC filings utilized standard risk factor language without specifying known issues affecting the Anaphylm NDA, leaving investors unaware of the actual risk profile.
- Legal Challenge: A lawsuit has been filed by investors questioning the company's failure to disclose specific regulatory hurdles, arguing that generic risk warnings cannot substitute for specific known issues, thereby undermining investor rights.
- Investor Rights Protection: Levi & Korsinsky LLP is evaluating the eligibility of affected investors for claims, with a deadline of May 4, 2026, highlighting the importance of legal support for investor rights and recovery of losses.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, seeking damages for investors who purchased securities between June 16, 2025, and January 8, 2026, highlighting serious concerns over the company's compliance and transparency.
- Legal Allegations Details: The complaint alleges that the defendants made materially false and misleading statements and failed to disclose critical information during the relevant period, potentially leading to investor losses and exacerbating market concerns regarding the company's financial health.
- Investor Participation Opportunity: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, allowing them to share in any potential recovery from the lawsuit, thus providing a chance for investors to recover losses.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in investor rights and securities fraud class actions, having recovered hundreds of millions for investors, underscoring its significant role in upholding market integrity.
See More
